Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
AUTOR(ES)
Piscitelli, S C
RESUMO
The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=164214Documentos Relacionados
- Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children
- Single-dose pharmacokinetics of aztreonam in pediatric patients.
- Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
- Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
- Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients.
